Although MEK TKIs and EGFR TKIs have overlapping toxicity (Satoh et al, 2020), recent results from the TATTON trial reported that an appropriate dosing schedule allows tolerable toxicity in EGFR-mutated NSCLC (Yang et al, 2022). This evidence concerns the gene EGFR and non-small cell lung carcinoma.